These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12818293)

  • 1. Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A.
    Albanese A; Brisinda G; Bentivoglio AR; Maria G
    Am J Gastroenterol; 2003 Jun; 98(6):1439-40. PubMed ID: 12818293
    [No Abstract]   [Full Text] [Related]  

  • 2. Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment.
    Cadeddu F; Bentivoglio AR; Brandara F; Marniga G; Brisinda G; Maria G
    Aliment Pharmacol Ther; 2005 Nov; 22(10):997-1003. PubMed ID: 16268975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin for cricopharyngeal dysfunction in Parkinson's disease.
    Restivo DA; Palmeri A; Marchese-Ragona R
    N Engl J Med; 2002 Apr; 346(15):1174-5. PubMed ID: 11948283
    [No Abstract]   [Full Text] [Related]  

  • 4. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
    Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
    Mov Disord; 2006 May; 21(5):704-7. PubMed ID: 16440332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin injections to one leg alleviate freezing of gait in a patient with Parkinson's disease.
    Giladi N; Honigman S
    Mov Disord; 1997 Nov; 12(6):1085-6. PubMed ID: 9399243
    [No Abstract]   [Full Text] [Related]  

  • 6. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
    Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
    J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?
    Nóbrega AC; Rodrigues B; Torres AC; Enzo A; Melo A
    J Neurol Sci; 2007 Feb; 253(1-2):85-7. PubMed ID: 17229441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin type A in the treatment of sialorrhea in Parkinson's disease.
    Melo A; Rodrigues B; Nóbrega AC
    J Am Geriatr Soc; 2009 Jan; 57(1):180; author reply 180-1. PubMed ID: 19170803
    [No Abstract]   [Full Text] [Related]  

  • 9. Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson's disease.
    Triadafilopoulos G; Gandhy R; Barlow C
    Parkinsonism Relat Disord; 2017 Nov; 44():33-37. PubMed ID: 28847681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type A for the treatment of gastroparesis in Parkinson's disease patients.
    Gil RA; Hwynn N; Fabian T; Joseph S; Fernandez HH
    Parkinsonism Relat Disord; 2011 May; 17(4):285-7. PubMed ID: 21296606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study.
    Gurevich T; Peretz C; Moore O; Weizmann N; Giladi N
    Mov Disord; 2007 Apr; 22(6):880-3. PubMed ID: 17290455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe constipation in Parkinson's disease relieved by botulinum toxin.
    Albanese A; Maria G; Bentivoglio AR; Brisinda G; Cassetta E; Tonali P
    Mov Disord; 1997 Sep; 12(5):764-6. PubMed ID: 9380063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin: from life-threatening disease to novel medical therapy.
    Mahajan ST; Brubaker L
    Am J Obstet Gynecol; 2007 Jan; 196(1):7-15. PubMed ID: 17240220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
    Giannantoni A; Mearini E; Del Zingaro M; Santaniello F; Porena M
    BJU Int; 2008 Jul; 102 Suppl 1():2-6. PubMed ID: 18665971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin type A as an adjuvant treatment modality for extensive Hailey-Hailey disease.
    Koeyers WJ; Van Der Geer S; Krekels G
    J Dermatolog Treat; 2008; 19(4):251-4. PubMed ID: 18629693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.
    Kuo HC
    Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Digestive disorders in Parkinson's disease: gastric atony, malabsorption and constipation].
    Pérez-Macho L; Borja-Andrés S
    Rev Neurol; 2010 Feb; 50 Suppl 2():S55-8. PubMed ID: 20205143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexion contracture after total knee arthroplasty in a patient with Parkinson's disease: successful treatment with botulinum toxin type A.
    Shah SN; Hornyak J; Urquhart AG
    J Arthroplasty; 2005 Dec; 20(8):1078-80. PubMed ID: 16376267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin A for drooling in Parkinson's disease: a pilot study to compare submandibular to parotid gland injections.
    Kalf JG; Smit AM; Bloem BR; Zwarts MJ; Mulleners WM; Munneke M
    Parkinsonism Relat Disord; 2007 Dec; 13(8):532-4. PubMed ID: 17383926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisapride treatment of constipation in Parkinson's disease.
    Jost WH; Schimrigk K
    Mov Disord; 1993 Jul; 8(3):339-43. PubMed ID: 8341299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.